A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS (ADGVVEGF121.10NH) Delivered by NOGA-Guided/MYOSTAR Catheter in "No Option" Patients with Class II-IV Stable Angina.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS (ADGVVEGF121.10NH) Delivered by NOGA-Guided/MYOSTAR Catheter in "No Option" Patients with Class II-IV Stable Angina.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs Vascular endothelial growth factor 121 gene therapy (Primary)
  • Indications Angina pectoris; Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms NOVA
  • Sponsors GenVec
  • Most Recent Events

    • 03 Sep 2008 Status changed from active, no longer recruiting to completed, according to detail published in an abstract.
    • 03 Sep 2008 Results have been published as an abstract in the proceedings of the ESC Congress 2008: Annual Congress of the European Society of Cardiology.
    • 24 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top